Jury verdict favours AZ in Nexium litigation

JURY VERDICT FAVOURS ASTRAZENECA IN
NEXIUM ANTITRUST LITIGATION

AstraZeneca today announced that a jury in the US District Court for the District of Massachusetts returned a verdict in favour of AstraZeneca in a Multi-District antitrust case filed by various purchaser groups challenging the previous settlement of Nexium patent litigation with Ranbaxy.

AstraZeneca is pleased with the jury's verdict. The Company has always maintained that the plaintiffs' allegations were without merit.

All parties have appellate rights.

Two cases making similar allegations were filed by numerous purchasers in the state court in Pennsylvania and are still pending.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Esra Erkal-Paler                     +44 20 7604 8030 (UK/Global)
Vanessa Rhodes                    +44 20 7604 8037 (UK/Global)
Ayesha Bharmal                     +44 20 7604 8034 (UK/Global)
Jacob Lund                             +46 8 553 260 20 (Sweden)
Michele Meixell                       + 1 302 885 6351 (US)

Investor Enquiries
Thomas Kudsk Larsen            +44 20 7604 8199       mob: +44 7818 524185
Karl Hård                                 +44 20 7604 8123    mob: +44 7789 654364
Eugenia Litz                            +44 20 7604 8233       mob: +44 7884 735627
Christer Gruvris                       +44 20 7604 8126       mob: +44 7827 836825

5 December 2014

-ENDS-